N-glycyl-3,5,3',5'-tetraiodo-thyronine | 32795-68-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-glycyl-3,5,3',5'-tetraiodo-thyronine
• 英文别名: N-Glycyl-3,5,3',5'-tetrajod-thyronin；N-Glycyl-dl-thyroxin；N-Glycylthyroxine；2-[(2-Aminoacetyl)amino]-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
• CAS: 32795-68-9
• 化学式: C₁₇H₁₄I₄N₂O₅
• 分子量: 833.927
• InChiKey: LAYWYGIYRIUSEN-UHFFFAOYSA-N

物化性质

• 沸点：
  698.1±55.0 °C(Predicted)
• 密度：
  2.499±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  122
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-glycyl-3,5-diiodo-thyronine 在 ammonium hydroxide 、 碘 作用下， 生成 N-glycyl-3,5,3',5'-tetraiodo-thyronine
  参考文献：
  名称：

  Ashley; Harington, Biochemical Journal, 1928, vol. 22, p. 1441

  摘要：

  DOI：

文献信息

• Genetically engineered enzymes and their conjugates for diagnostic assays
  申请人：Abbott Laboratories

  公开号：US05843634A1

  公开（公告）日：1998-12-01

  This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate. The ligand binds with an antibody, an analyte or a binding molecule to an analyte and as a result of this binding, the enzymatic activity of the hybrid enzyme-ligand conjugate is modified or modulated.

  这项发明涉及基因工程酶、它们的配体缀合物、它们的制造方法以及它们在定性或定量分析中的应用。一种杂交酶，如AP-表位酶，在起始AP酶的活性位点附近插入了一个外源氨基酸残基（一个表位）。外源氨基酸残基与一个分析物结合，由于这种结合，杂交酶AP-表位的酶活性被改变。酶活性的变化取决于分析物的存在或数量。在另一实施例中，杂交酶由在AP的活性位点附近引入的一个半胱氨酸形成。杂交酶上的半胱氨酸作为配体（如茶碱、铁蛋白、甲状腺素或地高辛）缀合的位点，以形成杂交酶-配体缀合物。配体与抗体、分析物或与分析物结合的分子结合，由于这种结合，杂交酶-配体缀合物的酶活性被改变或调节。
• Prodrugs of T3 and T4 with enhanced bioavailability
  申请人：Moncrief Scott James

  公开号：US20070099841A1

  公开（公告）日：2007-05-03

  The invention relates to compositions of amino acid and peptide conjugates comprising T3 and/or T4. The T3 or T4 is covalently attached to at least one amino acid via the N-terminus, the C-terminus, a side chain of the peptide carrier, and/or interspersed within the peptide chain. Also discussed are methods for protecting and administering active agents and methods for treating thyroid disorders.
• [EN] PRODRUGS OF T3 AND T4 WITH ENHANCED BIOAVAILABILITY<br/>[FR] PROMEDICAMENTS DE T3 ET DE T4 PRESENTANT UNE BIODISPONIBILITE ACCRUE
  申请人：NEW RIVER PHARMACEUTICALS INC

  公开号：WO2007030577A2

  公开（公告）日：2007-03-15

  [EN] The invention relates to compositions of amino acid and peptide conjugates comprising T3 and/or T4. The T3 or T4 is covalently attached to at least one amino acid via the N-terminus, the C-terminus, a side chain of the peptide carrier, and/or interspersed within the peptide chain. Also discussed are methods for protecting and administering active agents and methods for treating thyroid disorders.
  [FR] L'invention concerne des compositions de conjugués d'acides aminés et de peptides comprenant T3 et/ou T4. Le T3 ou le T4 est fixé de manière covalente à au moins un acide aminé par l'élément N-terminal, l'élément C-terminal, une chaîne latérale du support peptidique, et/ou est intercalé à l'intérieur d'une chaîne peptidique. L'invention concerne également des méthodes pour protéger et pour administrer des prinicipes actifs ainsi que des méthodes pour traiter des troubles thyroïdiens.